Abstract Acute unilateral vestibulopathy (AUV) is characterized by acute vertigo, nausea, and imbalance without neurological deficits or auditory symptomatology. Here, we explore the effect of glucocorticoid treatment on the degree of canal paresis in patients with AUV, and critically, establish its relationship with dizziness symptom recovery. We recruited consecutive patients who were retrospectively assigned to one of the two groups according to whether they received glucocorticoid treatment (n = 32) or not (n = 44). All patients underwent pure-tone audiometry, bithermal caloric testing, MRI brain imaging, and were asked to complete a dizziness handicap inventory on admission to hospital and just prior to hospital discharge. In the treatment group, the canal paresis at discharge was significantly lower than in the control group (mean ± SD % 38.04 ± 21.57 versus 82.79 ± 21.51, p \ 0.001). We also observed a significant reduction in the intensity of nystagmus in patients receiving glucocorticoid treatment compared to the non-treatment group (p = 0.03). DHI test score was significantly lower at discharge in the treatment group (mean ± SD % 23.15 ± 12.40 versus 64.07 ± 12.87, p \ 0.001), as was the length of hospital stay (2.18 ± 1.5 days versus 3.6 ± 1.7 days, p = 0.002). Glucocorticoid treatment leads to acute symptomatic improvement, with a reduced hospital stay and reduction in the intensity of acute nystagmus. Our findings suggest that glucocorticoids may accelerate vestibular compensation via a restoration of peripheral vestibular function, and therefore has important clinical implications for the treatment of AUV.
Introduction
Acute unilateral vestibulopathy (AUV) is characterized by sudden onset of rotational vertigo, nausea, and imbalance associated with intense autonomic symptoms, in the absence of neurological deficits or auditory symptoms [5] . AUV is caused by a sudden unilateral vestibular loss of function causing an asymmetry in the resting tone of the vestibular nerves that is responsible for the nystagmus and ensuing perception of vertigo. The symptoms of AUV gradually improve over time as a result of a process of vestibular compensation with eventual restitution of vestibular function in the majority of patients [1] .
The etiology of vestibular neuritis remains controversial and whilst labyrinthine ischaemia has been proposed, for the majority of patients, the natural history of the condition hints at an inflammatory cause, possibly due to reactivation of neurotropic viruses [2, 22] . One study probed the effects of corticosteroids with and without antivirals and concluded that methylprednisolone, but not valacyclovir, improves the recovery of vestibular function in these patients [21] . Other studies have confirmed the effects of glucocorticoids on peripheral vestibular function following acute AUV [18, 20] . Surprisingly, however, only one study has indirectly assessed the effects of glucocorticoids on dizziness symptoms in AUV, finding no long-term benefit [20] . The focus has instead been on canal paresis recovery, a surrogate marker of the vestibulo-ocular reflex. Despite asymmetrical VOR time constants following an acute vestibulopathy, recent evidence has shown a considerable dissociation between vestibulo-ocular and vestibulo-perceptual thresholds (i.e., the perception of self-motion) [7] . This poses the question of whether restoring the vestibular tone imbalance acutely-and thus reducing nystagmusthrough a reduction in inflammation would have any effect on dizziness symptoms (i.e., whether central compensatory mechanisms actuate to reduce self-motion perception (and thus dizziness) too quickly for glucocorticoids to be effective).
The primary aims of this study were, therefore, to explore the acute effect of glucocorticoid treatment on dizziness symptom recovery and length of hospital stay.
Materials and methods
We recruited consecutive patients with a clinical diagnosis of AUV presenting to the Department of Oto-RhinoLaryngology, Head and Neck Surgery at Salamanca University Hospital between March 2005 and April 2012. All patients were assessed by two experienced neurootologists to ensure that diagnostic criteria were rigorous and consistent throughout the recruitment period. Diagnostic criteria for AUV included a history of sudden onset of dizziness without auditory or neurological symptoms, contralesional spontaneous unidirectional horizontalrotational nystagmus, increasing in severity when visual fixation is abolished, ipsilesional abnormal head thrust test, and gait unsteadiness. Our center has routinely offered glucocorticoid treatment to all patients with AUV since September 2007.
All patients underwent pure-tone audiometry in the first or second day after the onset of symptoms, and a Fitzgerald and Hallpike bithermal caloric test on the fourth or fifth day, using video-oculography (Ulmer VNG, v. 1.4, SYNAPSIS, Marseille, France) that enables an objective measure of peripheral vestibular function and symmetry [9] . The maximum slow phase velocity (SPVmax) of nystagmus was calculated following each irrigation using an automated analysis incorporated into the system. The total caloric response from each ear (TotE) was calculated, and caloric weakness (CW) and directional preponderance (DP) were determined according to Jongkees' formula. Note that caloric testing was not performed prior to starting glucocorticoid therapy given that a thorough neuro-otological examination is felt to be sufficiently sensitive to correctly identify an acute unilateral vestibulopathy [24] , and to avoid delays in initiating treatment. Additionally, in accordance with local clinical guidelines for patients presenting with an acute vestibulopathy, all patients underwent magnetic resonance imaging (MRI) of the brain on the fourth or fifth day following symptom onset.
Video head impulse test and vestibular evoked myogenic potential data were not available for the majority of the patients tested, given the relatively recent introduction of these techniques into routine clinical practice, and are therefore not reported here. The Dizziness Handicap Inventory Dizziness Handicap Inventory (DHI) was also completed by the patient at the time of hospital discharge (mean duration to completion was 4.2 days). The DHI is a qualitative questionnaire used to quantify the self-perceived level of handicap associated with the symptom of dizziness in everyday life. It is a widely used, validated, and standardized test for patients with dizziness and unsteadiness [14, 23] .
Patients were retrospectively assigned to one of the two groups according to whether they received glucocorticoid treatment or not, as part of a cohort study. All patients underwent daily review by a Consultant otolaryngologist during the in-patient stay. All patients were additionally treated with intravenous diazepam 5 mg twice daily for the first and second day only to treat potential autonomic symptomatology. Nausea and vomiting were treated with intravenous metoclopramide 10 mg every 8 h during the first day. Patients were encouraged to mobilise as soon as possible, and were instructed to follow self-guided validated Cawthorne-Cooksey vestibular rehabilitation exercises [6] .
Glucocorticoid treatment group
Patients in this group were consecutively recruited between September 2007 and April 2012. Patients were treated with intravenous methylprednisolone 1 mg/kg for 5 days. The dosage was subsequently halved for another 5 days and then discontinued. The treatment protocol was based on local guidelines for the treatment of AUV established in 2007 and is similar to that used in Shupak et al. [20] and Karlberg and Magnusson [15] .
Control group
Patients in the no-glucocorticoid group were consecutively recruited between March 2005 and September 2007. In this group, patients were treated symptomatically with the same drugs and dosage as the treatment group patients but did not receive glucocorticoid.
Statistical analysis
Student's t test for unpaired observations was used to compare the data of the glucocorticoid treatment group with the control groups, following confirmation that the data met assumptions of equal variances (verified with Levene's test for equality of variances) and the data was normally distributed (Kolmogorov-Smirnov test). The analysis was performed using SPSS Statistics version 19. A p \ 0.05 was considered to be statistically significant.
Results

Clinical data
Demographic and clinical data are presented in Table 1 . The glucocorticoid treatment group comprised 32 patients (17 men and 15 women) and the control group 44 patients (23 men and 21 women). Age was not statistically different between groups (mean ± SD age 51.74 ± 15.32 versus 57.51 ± 18.35 years, p = 0.18 Student's t test for unpaired observations). No major adverse effects of the glucocorticoid treatment group were observed but glycemic control was needed in five patients.
Magnetic resonance imaging of the brain was normal in all patients in the treatment group but four patients were excluded from the study on the basis of abnormal findings on magnetic resonance imaging of the brain (2 patients with infarcts in the territories of the posterior inferior cerebellar artery and 2 patients with cerebellopontine angle lesions).
In-patient hospital stay differed significantly between groups (2.8 ± 1.5 days for the treatment group and 3.6 ± 1.7 days for the control group; p = 0.002). Fig. 1a ).
Oculomotor function
At hospital admission 27 patients from the treatment group had grade III nystagmus, and 5 had grade II, compared to 36 with grade III, and 8 with grade II nystagmus in the control group (p = 0.07; ANOVA). At hospital discharge, 20 patients from the treatment group had grade I nystagmus, 8 grade II nystagmus, and 4 grade III nystagmus, whereas in the control group, 21 had grade I nystagmus, 15 grade II nystagmus, and 8 grade III nystagmus (p = 0.03; ANOVA).
Dizziness Handicap Inventory
Dizziness Handicap Inventory test score at discharge was significantly lower in the treatment group (mean ± SD % 23.15 ± 12.40 (physical (P) = 8.05; functional (F) = 7.47; emotional (E) = 8.13) versus 64.07 ± 12.87 (P = 20.31; F = 19.56; E = 24.06), p \ 0.001 Student's t test for unpaired observations, Fig. 1b) .
Discussion
This study confirms prior reports showing peripheral vestibular function improvement in patients with AUV receiving glucocorticoids on admission [3, 20, 21] . Additionally, we have shown that the improvement in canal paresis with glucocorticoid treatment correlates with a reduction in the degree of nystagmus. Critically, however, we show here that acute glucocorticoid treatment reduces symptom load and hospitalization in patients with AUV.
Previous studies hinted that glucocorticoids may not be clinically beneficial in AUV [10] , despite apparent improvement in vestibular function [3, 15, 17, 20] . Indeed, both a systematic review [13] and later a Cochrane review of four trials found no significant difference between corticosteroid and placebo in the symptomatic recovery of vestibular function [11] , but only one study had assessed symptom recovery [20] , and this was not a primary study outcome. The short follow-up period in our study does not make the results with those of Shupak et al. [20] directly comparable, but one possibility is that the reduction in acute dizziness symptoms was related to the psychotropic effects of glucocorticoids [8] in our treatment group. Against this hypothesis is that euphoric sequelae of steroids in some patients (better DHI scores) would perhaps be counter-balanced by depressive and anxiety-related side effects [8] in other patients (worse DHI scores). Moreover, that improvements were seen with glucocorticoids across all functional, physical, and emotional DHI subscores further suggests that the effects of treatment are not limited to emotional aspects only (as one might expect for purely psychotropic steroid effects). Whether or not psychotropic effects of glucocorticoids have influenced the lower dizziness scores in these patients, the consequent reduction in hospital stay in the treatment group is a consistent [15] and important clinical finding where healthcare resources are financially constrained. Furthermore, patients with acute symptomatic improvement may be less likely to develop secondary non-vertiginous psychological symptoms in the long term, thus reducing chronic disease burden in this patient population. Further work will be needed to explore this concept.
An alternative, non-mutually exclusive hypothesis to explain the lower DHI scores in the treatment group is that glucocorticoid treatment may have an acute physiological effect on the vestibular nerve. Treatment with glucocorticoids in animal models of unilateral vestibular failure accelerates vestibular compensation-a central phenomenon triggered by a disturbance in peripheral firing rates of the vestibular nerve [19] . Reducing inflammation acutely with glucocorticoids may restore ipsilesional vestibular tone and thus reduce the degree of asymmetry, facilitating compensatory processes. Indeed, the improvement in the degree of nystagmus at hospital discharge in the glucocorticoid arm suggests that the glucocorticoids may be preferentially acting at the peripheral level, rather than centrally.
Our study has some limitations. Firstly, whilst shortterm symptomatic improvement in patients receiving glucocorticoids, in conjunction with reduced hospital stay, may be sufficient clinical indication to treat AUV with glucocorticoids acutely, an appreciation of long-term symptomatic outcomes remains an important unanswered question. The clinical use of glucocorticoids to reduce acute symptoms without altering the natural course of the condition is, however, an established practice in neurology, for example in multiple sclerosis [12] . Secondly, patients were retrospectively assigned to the treatment group based on current and previous clinical practice. Lastly, we have used a single measure of symptomatic recovery in patients. Nevertheless, whilst other dizziness questionnaires explore symptom severity and psychological measures of anxiety and depression in more depth, the DHI is a simple, clinically applicable test that is sensitive to change with interventions [4] and correlates well with objective measures of balance [16] .
In conclusion, our data suggest that glucocorticoids may accelerate vestibular compensation perhaps via a restoration of peripheral vestibular function, given the observed reduced nystagmus intensity in the treatment group. This finding has important clinical implications for the treatment of AUV, although further studies will need to assess whether acute administration of glucocorticoid treatment alters long-term outcome in these patients, and directly explore the underlying mechanism of human vestibular compensation in relation to glucocorticoid administration.
